LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS FROM CHINA, BRAZIL, AND SOUTH KOREA WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: RESULTS AT 64 WEEKS

被引：0
|
作者：
Zeng, X. [1 ,2 ]
Zhao, D. [3 ]
Radominski, S. [4 ]
Keiserman, M. [5 ]
Lee, C. K. [6 ]
Martin, N. [7 ]
Meerwein, S. [8 ]
Sui, Y. [9 ]
Park, W. [10 ]
机构：
[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp PUMCH, Beijing, Peoples R China
[2] Natl Clin Res Ctr Dermatol & Immunol Dis NCRC DID, Dermatol & Immunol, Beijing, Peoples R China
[3] Shanghai Changhai Hosp, Rheumatol & Immunol, Shanghai, Peoples R China
[4] Univ Fed Parana, Rheumatol, Curitiba, Parana, Brazil
[5] Pontifical Catholic Univ, Rheumatol, Porto Alegre, RS, Brazil
[6] Asan Med Ctr, Rheumatol, Seoul, South Korea
[7] AbbVie Inc, Immunol, Montreal, PQ, Canada
[8] AbbVie Deutsch GmbH & Co KG, Immunol, Ludwigshafen, Germany
[9] AbbVie Inc, Immunol, N Chicago, IL USA
[10] Inha Univ, Sch Med, Rheumatol, Incheon, South Korea
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.1807
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0260
引用
收藏
页码：1156 / 1157
页数：2
相关论文
共 50 条
  • [1] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS FROM CHINA, BRAZIL, AND SOUTH KOREA WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE -MODIFYING ANTIRHEUNLVEIC DRUGS: RESULTS NE 64 WEEKS
    Zeng, Xiaofeng
    Zhao, Dongbao
    Radominski, Sebastiao
    Keiserman, Mauro
    Lee, Chang K.
    Martin, Naomi
    Meerwein, Sebastian
    Sui, Yunxia
    Park, Won
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S104 - S104
  • [2] Efficacy and Safety of Upadacitinib in Patients from China, Brazil, and South Korea with Rheumatoid Arthritis Who Have Had Inadequate Response to Conventional Synthetic Disease-modifying Antirheumatic Drugs
    Zeng, Xiaofeng
    Zhao, Dongbao
    Radominski, Sebastiao
    Keiserman, Mauro
    Lee, Chang Keun
    Meerwein, Sebastian
    Enejosa, Jeffrey
    Sui, Yunxia
    Mohamed, Mohamed-Eslam
    Park, Won
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [3] EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS FROM CHINA, BRAZIL, AND SOUTH KOREA WITH RHEUMATOID ARTHRITIS WHO HAVE HAD INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    Zeng, X.
    Zhao, D.
    Radominski, S.
    Keiserman, M.
    Lee, C. K.
    Meerwein, S.
    Enejosa, J.
    Sui, Y.
    Mohamed, M. E.
    Park, W.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1016 - 1017
  • [4] EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS FROM CHINA BRAZIL, AND SOUTH KOREA WITH RHEUMATOID ARTHRITIS WHO HAVE HAD INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING NTIRHEUMATIC DRUGS
    Zeng, Xiaofeng
    Zhao, Dong-Boa
    Radominski, Sebastian
    Keiserman, Mriuro
    Lee, Chang Keun
    Meerwein, Sebastian
    Enejosa, Jeffery
    Sui, Yunxia
    Mohamed, Mohamed-Eslam
    Park, Won
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 98 - 99
  • [5] Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)
    Burmester, Gerd R.
    van den Bosch, Filip
    Tesser, John
    Shmagel, Anna
    Liu, Yanxi
    Khan, Nasser
    Camp, Heidi S.
    Kivitz, Alan
    [J]. JOURNAL OF RHEUMATOLOGY, 2024, 51 (07) : 663 - 672
  • [6] EFFICACY AND SAFETY OF UPADACITINIB IN A CHINESE SUBGROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Zeng, X.
    Liu, Y.
    Hu, J.
    Li, J.
    Wang, Y.
    Zhao, D.
    Wu, L.
    Xiao, Z.
    Li, Z.
    Xu, J.
    Meerwein, S.
    Xie, Y.
    Liang, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1324 - 1324
  • [7] Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks
    Burmester, Gerd
    Van den Bosch, Filip
    Bessette, Louis
    Kivitz, Alan
    Li, Yihan
    Friedman, Alan
    Pangan, Aileen
    Camp, Heidi
    Kremer, Joel
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [8] Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy
    Zeng, Xiaofeng
    Zhao, Dongbao
    Radominski, Sebastiao C.
    Keiserman, Mauro
    Lee, Chang K.
    Meerwein, Sebastian
    Enejosa, Jeffrey
    Sui, Yunxia
    Mohamed, Mohamed-Eslam F.
    Park, Won
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2021, 24 (12) : 1530 - 1539
  • [9] Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
    Strand, Vibeke
    Pope, Janet
    Tundia, Namita
    Friedman, Alan
    Camp, Heidi S.
    Pangan, Aileen
    Ganguli, Arijit
    Fuldeore, Mahesh
    Goldschmidt, Debbie
    Schiff, Michael
    [J]. ARTHRITIS RESEARCH & THERAPY, 2019, 21 (01)
  • [10] Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
    Vibeke Strand
    Janet Pope
    Namita Tundia
    Alan Friedman
    Heidi S. Camp
    Aileen Pangan
    Arijit Ganguli
    Mahesh Fuldeore
    Debbie Goldschmidt
    Michael Schiff
    [J]. Arthritis Research & Therapy, 21
12345